Turno is a fintech startup focused on facilitating the transition to electric vehicles (EVs) for commercial vehicle operators and owners. The company offers a variety of vehicles from multiple original equipment manufacturers (OEMs) and provides affordable financing solutions along with battery value guarantees to protect the investments of EV purchasers. Turno aims to convert gasoline miles to electric miles, catering specifically to the needs of operators in the delivery sector. Its platform supports both online and physical sales of EVs, while also offering services such as the buyback of used batteries, thereby enhancing the overall value proposition for its customers in India.
Nanjing IASO Biotherapeutics is a clinical-stage biotechnology company established in 2017, specializing in the development of innovative therapies for cancer treatment. The company focuses on creating engineered autologous and allogenic T cell therapies aimed at enhancing the immune system's ability to identify and eliminate cancer cells. Its work centers on the discovery, development, and potential commercialization of cell therapies specifically in the oncology sector, striving to advance cancer care through these advanced therapeutic approaches. Based in Nanjing, China, IASO Biotherapeutics is dedicated to addressing the challenges posed by cancer through its targeted treatment solutions.
CellOrigin Biotech specializes in the development of innovative therapeutics using induced pluripotent stem cells (iPSCs) to create innate immune cells. The company is dedicated to advancing immune cell technology aimed at treating solid tumors. Its research focuses on the generation of gene-manipulated, clinically applicable iPSCs and the establishment of a clinical iPSC bank. Additionally, CellOrigin Biotech is developing an efficient platform for differentiating iPSCs into mature stem cells, which enhances their potential for therapeutic applications. Through these efforts, the company aims to contribute significantly to the field of cancer treatment.
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.
Cloudbreak Therapeutics LLC is a clinical-stage biotechnology company based in Irvine, California, focused on developing ocular drugs for conditions such as glaucoma and pterygium. Founded in 2015, the company utilizes a capital-efficient business model that repurposes approved systemic drugs for ocular delivery. By prioritizing the rapid advancement of drug candidates through proof-of-concept Phase II clinical trials, Cloudbreak Therapeutics aims to out-license global rights for Phase III trials, product registration, and commercialization. The company strategically collaborates with contract research organizations to manage non-clinical, chemistry, manufacturing, and clinical development, thus maximizing its resources for effective drug development.
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.
Beino Bio is a China-based supplier of biopharmaceutical CDMO and cell culture media, providing process development and GMP production services for companies interested in introducing protein, cell therapy and gene therapy drugs to the Chinese and global markets.
CirCode
Seed Round in 2021
CirCode utilizes mRNA biotechnology to develop new biomedicine and drugs.
JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recently received angel round investment.
Developer of biopharmaceutical technology intended for innovative drugs. The company is mainly engaged in the research and development of long-acting recombinant protein innovative drugs for hemophilia, metabolic disease and tumor, enabling patients with protein drugs.
3D Medicines, we use individual’s genetic information to prevent, diagnose, and treat cancer. We develop personalized medicines according to target population’s genetic background, to increase efficacy and safety.
Shenzhen InnerMedical Medical Technology Co., Ltd., founded in 2015 and based in Shenzhen, China, specializes in the research and development of advanced medical imaging techniques. The company focuses on creating minimally invasive imaging devices to enhance diagnosis and treatment for cancer, cardiovascular, and cerebrovascular diseases. Its product offerings include intravascular imaging systems, high-frequency ultrasound endoscopes, electronic endoscopes, and medical protective goggles. InnerMedical aims to provide innovative catheter imaging solutions that contribute to more accurate medical assessments and improved patient outcomes.
OBiO Technology is a biotechnology company specializing in gene therapy solutions. It offers contract research organization (CRO) services focused on the development of gene therapy vectors, gene function research, and drug target efficacy. The company also provides contract development and manufacturing organization (CDMO) services, which include process development, testing, and IND-CMC pharmaceutical research. Additionally, OBiO Technology supports the production of clinical samples under Good Manufacturing Practices (GMP) for genetic drug research and development. Through its comprehensive offerings, the company aims to advance the field of gene therapy and facilitate the development of innovative therapeutic solutions.
SiBionics is medtech comppany specialized in the R&D and commercialization of active implantable medical devices and medical artificial intelligence. The company is based in Shenzhen, China.
OBiO Technology is a biotechnology company specializing in gene therapy solutions. It offers contract research organization (CRO) services focused on the development of gene therapy vectors, gene function research, and drug target efficacy. The company also provides contract development and manufacturing organization (CDMO) services, which include process development, testing, and IND-CMC pharmaceutical research. Additionally, OBiO Technology supports the production of clinical samples under Good Manufacturing Practices (GMP) for genetic drug research and development. Through its comprehensive offerings, the company aims to advance the field of gene therapy and facilitate the development of innovative therapeutic solutions.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Beijing WeMed Medical Equipment Co., Ltd. specializes in interventional diagnosis and treatment solutions, focusing on the development and industrialization of digital angiography systems. Founded in 2014 and based in Beijing, China, the company serves the clinical fields of radiology and cardiology. WeMed not only creates advanced digital angiography machines but also actively engages in optimizing and upgrading its products. Additionally, the company arranges department operations and conducts training for medical professionals, ensuring effective implementation and use of its technology. As a subsidiary of TCL Technology Group Corporation, WeMed is committed to advancing healthcare through innovative medical equipment and comprehensive support services.
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.
TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy product preparation, enabling better tumor therapy outcome.
Zhongyianke Biotech is a Tianjin-based company specializing in the development and provision of human vaccines. Founded in 2001, it operates as a subsidiary of Qinhuangdao Gangyuan Real Estate Group Co., Ltd. The company has launched a flu vaccine and is currently conducting clinical trials for several other vaccines, including a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. Zhongyianke Biotech holds 14 patents in China, underscoring its commitment to innovation in the vaccine sector. In addition to its headquarters in Tianjin, the company maintains a research and development center in Beijing and a production facility in Liaoning Province, enhancing its operational capabilities in vaccine development and manufacturing.
Tactiva Therapeutics, LLC is an immuno-oncology company focused on developing innovative cancer immunotherapy solutions. Established in 2016 and located in Buffalo, New York, the company specializes in adoptive cell therapy that employs a dual T cell receptor approach. Its platform incorporates engineered CD4 and CD8 T cells, which work together to provide both direct anti-tumor activity and sustained support for T cell-derived effector cells. This strategy aims to enhance the effectiveness of cancer treatments, allowing healthcare professionals to better diagnose and manage life-threatening diseases.
Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013 and based in Boston, Massachusetts, the company’s product pipeline includes CNTX-4975, currently undergoing Phase III trials for knee osteoarthritis pain and Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials for various chronic pain conditions, while CNTX-6970 targets inflammatory pain and CNTX-2022, a high-concentration topical gel formulation of lidocaine, is also in Phase I trials for superficial musculoskeletal pain and related conditions. Furthermore, CNTX-6016 is a pre-clinical candidate aimed at treating chronic neuropathic pain. Centrexion Therapeutics is committed to addressing the unmet medical needs in chronic pain treatment by focusing on safety and efficacy.
Lifotronic is a developer of physiotherapy and medical equipment designed to offer effective medical treatment and recovery system within the medical devices sector. The company's equipment includes liquid chromatography, nephelometry and lateral flow immunoassay, enabling healthcare providers to create value and improve the lives of patients.
Shenzhen Chipscreen Biosciences Co., Ltd. is a biotechnology company based in Shenzhen, China, specializing in the research, development, and sale of original small molecule drugs. Founded in 2001, the company focuses on creating new drug candidates for various therapeutic areas, including cancer, metabolic diseases, and autoimmune diseases. Chipscreen employs a proprietary chemical genomics-based discovery platform, which has facilitated the development of both clinical and preclinical programs. The company collaborates with partners for the co-development and commercialization of its drug candidates, leveraging its expertise in intellectual property and regulatory matters. Through its science-driven approach and strong pipeline-building capabilities, Chipscreen aims to establish itself as a leader in drug discovery and pharmaceuticals in China.
Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company's lead candidate, AR-301, is a fully human IgG1 mAb currently undergoing Phase III trials for treating lung infections linked to S. aureus alphatoxin. Additionally, Aridis is developing several other mAb candidates, including AR-105, in Phase II trials for P. aeruginosa infections, and AR-101, which targets hospital-acquired pneumonia caused by P. aeruginosa serotype O11. Other projects include AR-401, in preclinical stages for Acinetobacter baumannii infections, and AR-201, a preclinical IgG1 mAb for respiratory syncytial virus. The company also has AR-501, an anti-infective therapy in Phase I/IIa clinical trials aimed at managing chronic lung infections in cystic fibrosis patients, as well as acute pneumonia in hospital-acquired pneumonia and ventilator-associated pneumonia settings. Founded in 2003, Aridis is headquartered in San Jose, California.
Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company based in Nanjing, China, established in 2013. The company specializes in discovering, developing, manufacturing, and commercializing innovative medicines aimed at improving patient health, particularly in the areas of anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch for managing musculoskeletal joint pain. Additionally, Frontier Biotech is developing a combination regimen of Albuvirtide and a monoclonal antibody to combat HIV-1. The company's first product received accelerated approval from the National Medical Product Administration in May 2018, marking a significant milestone in its commercial journey. Currently, two other drug candidates are in Phase I and II clinical trials in both China and the United States. Frontier Biotechnologies combines expertise from various fields, including research and development, management, and marketing, to establish itself as a competitive player in the global market for long-acting HIV treatments and immunotherapy.
KBP Biosciences Co., Ltd. is a biotechnology company based in Jinan, China, with additional offices in Beijing, Japan, and the United States. Founded in 2002, the company focuses on the research and development of drugs targeting infectious and metabolic diseases. Its comprehensive research platform employs structure-based drug design, in vitro and cell-based biological screening, and pharmacodynamic and pharmacokinetic evaluation, alongside ADME profiling and pre-clinical animal pharmacology and toxicity analysis. KBP Biosciences also offers services related to the transfer of new drugs, licensing, and intellectual property protection, which includes patent scope analysis, novelty analysis, and patent writing and filing. The organization is committed to delivering innovative therapies to address unmet medical needs.
Shenzhen UniHz Technologies Corporation is a developer of intelligent transportation software and solutions, specializing in urban traffic management. Founded in 2002 and headquartered in Shenzhen, China, the company focuses on research and development in the field of intelligent transportation. It aims to integrate application solutions with product development and manufacturing to enhance traffic management systems. As of November 2020, UniHz operates as a subsidiary of Ping An International Smart City Technology Co., Ltd., further strengthening its capabilities in the smart city sector.